Atria Investments Inc Has $364,000 Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Atria Investments Inc lowered its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 7.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,101 shares of the medical device company’s stock after selling 855 shares during the quarter. Atria Investments Inc’s holdings in Tandem Diabetes Care were worth $364,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of TNDM. Baillie Gifford & Co. grew its position in Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after purchasing an additional 523,843 shares during the period. GW&K Investment Management LLC lifted its stake in Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after acquiring an additional 323,674 shares in the last quarter. Bellevue Group AG lifted its stake in Tandem Diabetes Care by 19.9% during the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock valued at $78,496,000 after acquiring an additional 307,624 shares in the last quarter. Stephens Investment Management Group LLC lifted its stake in Tandem Diabetes Care by 22.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock valued at $56,040,000 after acquiring an additional 281,327 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Tandem Diabetes Care by 397.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company’s stock valued at $11,121,000 after acquiring an additional 240,966 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Barclays dropped their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Royal Bank of Canada dropped their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Morgan Stanley cut Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th. Robert W. Baird lowered their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group lowered their target price on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.38.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Stock Up 5.4 %

Shares of NASDAQ TNDM opened at $19.17 on Monday. Tandem Diabetes Care, Inc. has a one year low of $17.64 and a one year high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The firm’s 50 day simple moving average is $31.38 and its two-hundred day simple moving average is $34.55. The stock has a market capitalization of $1.27 billion, a P/E ratio of -9.93 and a beta of 1.45.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.